Navigation Links
Cytochroma Announces Positive Comparative Data on CTA018 in Chronic Kidney Disease Model
Date:11/6/2008

replacement therapies (paricalcitol, doxercalciferol and calcitriol) can over-stimulate intestinal absorption of dietary calcium and phosphate, leading to excessive calcium and phosphorus in the blood. These toxicities severely limit the ability of physicians to fully control SHPT with such therapies. Data presented today demonstrate that CTA018 has significantly reduced activity and half-life in human enterocytes (intestinal cells), making CTA018 Injection far less likely to cause hypercalcemia (excessive blood calcium) or hyperphosphatemia (excessive blood phosphorus).

(3) CTA018 Preserves Vitamin D Status

Currently available vitamin D hormone replacement therapies exacerbate vitamin D insufficiency, which is widespread in CKD patients. Repeated administration of these therapies induces CYP24, and consequently depletes blood levels of calcifediol, a condition known as vitamin D insufficiency. Vitamin D insufficiency has been linked to increased mortality in CKD patients. In a preclinical study of adenine-induced CKD, repeated dosing with CTA018 did not decrease blood levels of calcifediol, possibly due to its potent CYP24 inhibitory activity.

(4) CTA018 Has Constant Potency and a Wider Therapeutic Window than Paricalcitol

Current vitamin D hormone replacement therapies can induce treatment resistance in CKD patients over time. Prolonged dosing often induces CYP24 to levels that create a barrier to administered therapy, limiting effectiveness. In a preclinical study of adenine-induced CKD, CTA018 was found to have consistent effectiveness in lowering parathyroid hormone (PTH) throughout a 4-week treatment period. In contrast, paricalcitol became progressively less effective. Additionally, CTA018 exhibited a wider therapeutic window than paricalcitol, having no significant impact on serum calcium or phosphorus at doses which fully controlled SHPT.

Current Status of CTA018 Injection

CTA018 Injection is in Phase II clinical de
'/>"/>

SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Retina, it has been found that a drug, which ... effective// in treating cystoid macular edema (CME), a common ... two patients with severe retinal swelling who were not ... Avastin, works in colorectal cancer by inhibiting the blood ...
... found that intake of foods during pregnancy plays a vital ... intake of diet// and behavior of child are interrelated, and ... less nutritious food at the time of pregnancy. ,Dr. ... study, which found that children born to iron-deficient teenage mothers ...
... Hospitals Trust has been fined ?100,000 after pleading guilty ... 31 following a routine operation//. The trust has pleaded ... ,Sitting at Winchester Crown Court, Mr Justice ... costs following the health and safety prosecution prompted by ...
... of the NHS, Sir Ian Carruthers, has proposed cost cutting ... ,He proposes to unveil his plan at a No ... believes the ?10.3 billion spent every year on drugs and ... Fears that patients would not be given expensive treatments from ...
... the William Harvey Research Institute has ... dark chocolate on heart patients//. He ... trial once he gets the regulatory ... with cardiovascular disease will be tested ...
... & Lomb Inc's brand cleansing solution has been linked to ... cause blindness//. Optometry doctors in the U.S have urged contact ... , Bausch & Lomb Inc. has ... since Monday following warnings from the U.S. Food and Drug ...
Cached Medicine News:Health News:Hospital Trust Fined ?100,000 after Patient Deat 2
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: